
How Pluvicto and Lutetium-177 Work in Prostate Cancer
Pluvicto, a lutetium-177 radioligand therapy, targets PSMA-positive metastatic prostate cancer — here's how it works and who qualifies.

Pluvicto, a lutetium-177 radioligand therapy, targets PSMA-positive metastatic prostate cancer — here's how it works and who qualifies.

Hearing 'chemo' for prostate cancer is frightening, but it's used only when the cancer has spread—often with hormone therapy. See when it helps and how.